BR0316101A - Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos - Google Patents

Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos

Info

Publication number
BR0316101A
BR0316101A BR0316101-3A BR0316101A BR0316101A BR 0316101 A BR0316101 A BR 0316101A BR 0316101 A BR0316101 A BR 0316101A BR 0316101 A BR0316101 A BR 0316101A
Authority
BR
Brazil
Prior art keywords
antibodies
same
anticd33
treating acute
leukemia
Prior art date
Application number
BR0316101-3A
Other languages
English (en)
Inventor
Mary G Hoffee
Daniel J Tavares
Robert J Lutz
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of BR0316101A publication Critical patent/BR0316101A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"ANTICORPOS ANTICD33 E PROCESSO PARA TRATAMENTO DE LEUCEMIA MIELóIDE AGUDA USANDO OS MESMOS". A presente invenção refere-se a anticorpos que se ligam a CD33. Mais particularmente, a invenção refere-se a anticorpos antiCD33, fragmentos e homólogos dos ditos anticorpos, versões humanizadas e de superfície nova dos ditos anticorpos, versões aperfeiçoadas e equivalentes funcionais dos ditos anticorpos, imunoconjugados e composições compreendendo os ditos anticorpos, e os usos dos mesmos em diagnóstico, pesquisa e aplicações terapêuticas. A invenção também refere-se a um polinucleotídeo codificando os anticorpos, vetores compreendendo os polinucleotídeos, células hospedeiras transformadas com polinucleotídeos e processos de produção de anticorpos.
BR0316101-3A 2002-11-07 2003-11-05 Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos BR0316101A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42433202P 2002-11-07 2002-11-07
PCT/US2003/032737 WO2004043344A2 (en) 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same

Publications (1)

Publication Number Publication Date
BR0316101A true BR0316101A (pt) 2005-09-27

Family

ID=32312793

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316101-3A BR0316101A (pt) 2002-11-07 2003-11-05 Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos

Country Status (25)

Country Link
US (10) US7557189B2 (pt)
EP (1) EP1578446B1 (pt)
JP (1) JP5354835B2 (pt)
KR (1) KR20050059332A (pt)
CN (2) CN1795009B (pt)
AU (1) AU2003285878B2 (pt)
BR (1) BR0316101A (pt)
CA (1) CA2504818C (pt)
CO (1) CO5580797A2 (pt)
CR (1) CR7853A (pt)
CY (1) CY1116406T1 (pt)
DK (1) DK1578446T3 (pt)
EA (1) EA010570B1 (pt)
EC (1) ECSP055831A (pt)
ES (1) ES2539627T3 (pt)
HK (1) HK1091132A1 (pt)
HU (1) HUE026914T2 (pt)
IL (2) IL168295A (pt)
MX (1) MXPA05004712A (pt)
NO (1) NO338498B1 (pt)
NZ (1) NZ539395A (pt)
PT (1) PT1578446E (pt)
SI (1) SI1578446T1 (pt)
WO (1) WO2004043344A2 (pt)
ZA (1) ZA200503075B (pt)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795009B (zh) * 2002-11-07 2014-07-09 伊谬诺金公司 抗-cd33抗体及其用途
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
EP1853322B1 (en) * 2005-02-11 2014-06-25 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2084527A4 (en) * 2006-11-02 2011-07-27 Seattle Genetics Inc METHOD FOR TREATING NEOPLASIA, AUTOIMMUNE AND INFLAMMATORY DISEASES
LT2644205T (lt) 2007-04-12 2018-12-10 The Brigham And Women`S Hospital, Inc. Nutaikymas į abcb5 vėžio terapijai
ES2435779T3 (es) 2007-07-19 2013-12-23 Sanofi Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
KR20220035504A (ko) 2008-04-30 2022-03-22 이뮤노젠 아이엔씨 가교제 및 그 용도
CN106188295A (zh) 2009-04-20 2016-12-07 牛津生物疗法有限公司 特异于钙粘素‑17的抗体
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
WO2011028683A1 (en) 2009-09-03 2011-03-10 Schering Corporation Anti-gitr antibodies
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
US8524240B2 (en) 2009-10-26 2013-09-03 Djordje Atanackovic Diagnosis and therapy of hematological malignancies
WO2011053783A2 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
JP2013520999A (ja) 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ５２に対するモノクローナル抗体
AU2011221553B2 (en) * 2010-03-04 2016-05-26 Vet Therapeutics Inc. Monoclonal antibodies directed to CD20
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
WO2012054084A2 (en) * 2010-10-20 2012-04-26 Oxford Biotherapeutics Ltd. Antibodies
WO2012074097A1 (ja) * 2010-12-03 2012-06-07 協和発酵キリン株式会社 抗ｃｄ３３抗体
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
US9534000B2 (en) 2011-02-15 2017-01-03 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
SI2691155T1 (sl) 2011-03-29 2019-03-29 Immunogen, Inc. Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
CA2836927A1 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
BR112014012539B1 (pt) 2011-11-23 2022-12-20 Medimmune, Llc Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CN102768283B (zh) * 2012-07-23 2015-03-04 北京大学人民医院 一种检测或辅助检测髓系白血病细胞分化阶段的试剂盒
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
RU2668824C2 (ru) 2012-08-31 2018-10-02 Иммьюноджен Инк. Диагностические анализы и наборы для детекции фолатного рецептора 1
SG10201702737TA (en) 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
PL2766048T3 (pl) 2012-10-12 2015-05-29 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
PT3016512T (pt) 2013-07-05 2020-02-24 H Lee Moffitt Cancer Ct & Res Cd33 solúvel para tratar síndromes mielodisplásicas (smd)
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EA201691214A1 (ru) * 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
CN105873614B (zh) * 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
KR102170533B1 (ko) 2014-04-03 2020-10-27 셀렉티스 암 면역요법을 위한 cd33 특이적 키메라 항원 수용체들
CA2948275C (en) 2014-04-08 2023-10-17 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
JP2017512765A (ja) 2014-04-11 2017-05-25 メディミューン，エルエルシー 二重特異性ｈｅｒ２抗体
WO2015179400A2 (en) * 2014-05-20 2015-11-26 Immunogen,Inc. Methods for characterizing and treating acute myeloid leukemia
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
MA42561A (fr) 2014-09-02 2018-04-25 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicament
PL3189056T3 (pl) 2014-09-03 2020-11-02 Immunogen, Inc. Cytotoksyczne pochodne benzodiazepinowe
JP2017527562A (ja) 2014-09-03 2017-09-21 イミュノジェン・インコーポレーテッド 細胞毒性ベンゾジアゼピン誘導体
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CA2962275C (en) * 2014-10-23 2019-11-05 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
JP6755866B2 (ja) 2014-11-10 2020-09-16 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
IL307913A (en) * 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
US11014989B2 (en) 2015-01-26 2021-05-25 Cellectis Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
AU2016271113B2 (en) 2015-05-29 2022-09-08 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
EP3307771A2 (en) * 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
SI3313845T1 (sl) 2015-06-29 2021-01-29 Immunogen, Inc. Konjugati spremenjenih protiteles cisteina
SI3313884T1 (sl) 2015-06-29 2021-04-30 Immunogen, Inc. Protitelesa proti CD123 ter njihovi konjugati in derivati
SI3374398T1 (sl) 2015-11-10 2020-07-31 Medimmune, Llc Vezavne molekule, specifične za ASCT2 in njihove uporabe
ES2873846T3 (es) 2015-11-19 2021-11-04 Revitope Ltd Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
EP3411077A1 (en) 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
EP3426680A4 (en) 2016-03-10 2020-03-11 Acceleron Pharma Inc. TYPE 2 ACTIVIN RECEPTOR BINDING PROTEINS AND USES THEREOF
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR20220119529A (ko) 2016-06-02 2022-08-29 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
US11191771B2 (en) 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
EP3515947B1 (en) * 2016-09-20 2024-05-29 Aronora, Inc. Novel antibodies against factor xi and uses thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
RU2019114863A (ru) * 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
CR20190297A (es) 2016-11-23 2019-11-01 Bioverativ Therapeutics Inc Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
US10287256B2 (en) 2016-11-23 2019-05-14 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
CN110366431B (zh) 2017-02-28 2023-07-18 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
MA49152A (fr) * 2017-05-17 2020-03-25 Immunogen Inc Schémas posologiques d'immunoconjugués anti-cd33
JP7299160B2 (ja) * 2017-08-03 2023-06-27 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
WO2019060707A1 (en) 2017-09-22 2019-03-28 Immunogen, Inc. METHODS FOR PREVENTING OXIDATION OF METHIONINE IN IMMUNOCONJUGATES
AU2018346955A1 (en) 2017-10-13 2020-04-30 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US20190160089A1 (en) 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
TWI827575B (zh) 2017-12-28 2024-01-01 美商伊繆諾金公司 苯二氮平衍生物
CN111989117A (zh) 2018-02-14 2020-11-24 维埃拉生物股份有限公司 麦克唐纳猫肉瘤(fms)样酪氨酸激酶3受体配体(flt3l)的抗体及其用于治疗自身免疫性疾病和炎性疾病的用途
JP7398380B2 (ja) * 2018-03-08 2023-12-14 フェインズ セラピューティクス，インコーポレーテッド 抗クローディン１８．２抗体及びその使用
JP7386800B2 (ja) * 2018-03-14 2023-11-27 メモリアル スローン－ケタリング キャンサー センター 抗ポリシアル酸抗体およびその使用
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
JP2021525068A (ja) * 2018-05-23 2021-09-24 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
SG11202101875VA (en) * 2018-08-28 2021-03-30 Ambrx Inc Anti-cd3 antibody folate bioconjugates and their uses
SG11202101552SA (en) 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3849565A4 (en) * 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2020068058A1 (en) * 2018-09-25 2020-04-02 Academia Sinica Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof
WO2020077258A1 (en) * 2018-10-12 2020-04-16 Jeanmarie Guenot Cd33×cd3 binding proteins for treating inflammatory conditions and diseases
SG11202103832SA (en) * 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
KR20220022112A (ko) 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법
JP2022529583A (ja) 2019-03-29 2022-06-23 イミュノジェン・インコーポレーテッド 異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス－ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体
WO2020219287A1 (en) 2019-04-26 2020-10-29 Immunogen, Inc. Camptothecin derivatives
CN114007642A (zh) 2019-04-30 2022-02-01 森迪生物科学公司 嵌合受体及其使用方法
US20230081720A1 (en) 2019-05-20 2023-03-16 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
JP2022538117A (ja) * 2019-06-26 2022-08-31 メモリアル スローン ケタリング キャンサー センター がんを処置するための抗ｃｄ３３抗体
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN116670268A (zh) 2019-11-22 2023-08-29 免疫医疗有限公司 包含e2泛素或泛素样缀合结构域和用于特异性蛋白质降解的靶向结构域的融合蛋白
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
US11795225B2 (en) 2020-09-11 2023-10-24 Medimmune Limited Therapeutic binding molecules
WO2022053685A2 (en) 2020-09-12 2022-03-17 Medimmune Limited A scoring method for an anti-b7h4 antibody-drug conjugate therapy
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
US20240115607A1 (en) 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AU2022236492A1 (en) 2021-03-18 2023-10-26 Medimmune Limited Therapeutic binding molecule that binds to ccr9
WO2022241057A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE69033631T2 (de) 1989-12-14 2001-05-17 Sloan Kettering Inst Cancer Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
ATE444309T1 (de) * 2000-08-08 2009-10-15 Immunomedics Inc Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper
CA2434762A1 (en) * 2001-01-26 2002-09-19 Joseph M. Patti Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
CN1795009B (zh) * 2002-11-07 2014-07-09 伊谬诺金公司 抗-cd33抗体及其用途
JP2008538365A (ja) * 2005-04-15 2008-10-23 イミュノジェン・インコーポレーテッド 腫瘍内の不均一または混合細胞集団を排除する方法
US8563700B2 (en) * 2008-06-16 2013-10-22 Immunogen, Inc. Synergistic effects
WO2015179400A2 (en) * 2014-05-20 2015-11-26 Immunogen,Inc. Methods for characterizing and treating acute myeloid leukemia

Also Published As

Publication number Publication date
DK1578446T3 (en) 2015-06-29
HUE026914T2 (en) 2016-08-29
EP1578446B1 (en) 2015-04-08
JP5354835B2 (ja) 2013-11-27
KR20050059332A (ko) 2005-06-17
ES2539627T3 (es) 2015-07-02
IL168295A (en) 2011-02-28
US20140248267A1 (en) 2014-09-04
US7342110B2 (en) 2008-03-11
AU2003285878B2 (en) 2011-04-28
CA2504818C (en) 2013-04-23
CY1116406T1 (el) 2017-02-08
CO5580797A2 (es) 2005-11-30
MXPA05004712A (es) 2005-11-23
EA010570B1 (ru) 2008-10-30
ZA200503075B (en) 2006-09-27
CN102875680A (zh) 2013-01-16
US8119787B2 (en) 2012-02-21
US20050118183A1 (en) 2005-06-02
US8747851B2 (en) 2014-06-10
AU2003285878A1 (en) 2004-06-03
US8337855B2 (en) 2012-12-25
US20160362490A1 (en) 2016-12-15
HK1091132A1 (en) 2007-01-12
JP2006505277A (ja) 2006-02-16
EP1578446A4 (en) 2008-07-30
CN1795009B (zh) 2014-07-09
NZ539395A (en) 2009-01-31
CN102875680B (zh) 2015-04-22
US20110008840A1 (en) 2011-01-13
IL211385A0 (en) 2011-04-28
EP1578446A2 (en) 2005-09-28
WO2004043344A3 (en) 2004-12-09
US9359442B2 (en) 2016-06-07
PT1578446E (pt) 2015-07-22
ECSP055831A (es) 2005-08-11
US20110206700A1 (en) 2011-08-25
WO2004043344A2 (en) 2004-05-27
NO338498B1 (no) 2016-08-22
CN1795009A (zh) 2006-06-28
US20180362646A1 (en) 2018-12-20
SI1578446T1 (sl) 2015-07-31
US10000566B2 (en) 2018-06-19
US20090291090A1 (en) 2009-11-26
US7557189B2 (en) 2009-07-07
CR7853A (es) 2005-12-16
NO20052693L (no) 2005-06-06
US20060177455A1 (en) 2006-08-10
EA200500778A1 (ru) 2006-02-24
CA2504818A1 (en) 2004-05-27
NO20052693D0 (no) 2005-06-06
US20080167458A1 (en) 2008-07-10
US20130078241A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
BR0316101A (pt) Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
BRPI0106682B8 (pt) molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
BR0212756A (pt) Molécula de anticorpo tendo especificidade para kdr humano, variante da molécula de anticorpo, composto, sequência de dna, vetor, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, e, uso da molécula de anticorpo
EA200800094A1 (ru) Антитела cd19 и их использование
BRPI0407833A (pt) anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio
BR0212136A (pt) Anticorpo monoclonal humano isolado, métodos para inibir a produção de tnfa em células t ou monócitos e a proliferação de célula t, hibridoma, transfectoma, animal não humano transgênico, método para produzir um anticorpo monoclonal humano, composição farmacêutica, métodos para tratar ou prevenir um distúrbio mediado pela il-15 humana, a psorìase e a artrite reumatóide, método para diagnosticar uma doença, ácido nucleico, e, vetor de expressão
BRPI0418766A (pt) anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1
ATE477277T1 (de) Weniger immunogene bindungsmoleküle
BR0209792A (pt) Anticorpos para vla-1
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
EA200600905A1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
BR0307994A (pt) Anticorpo monoclonal de antitenascina humana
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
DE69128543T2 (de) Monoklonale antikörper der maus
BR9908724A (pt) Polipeptìdeo, proteìna de fusão, composição, processos para tratar infecção fúngica e para determinar a presença de quitina em uma amostra, kit para diagnóstico da presença de quitina em uma amostra, vetor, célula hospedeira, processo para produzir um polipeptìdeo compreedendo um fragmento de quitinase humana, e, anticorpo monoclonal
Zhang et al. Purification and characterization of a DNA-binding heterodimer of 52 and 100 kDa from HeLa cells
EA200401453A1 (ru) Молекулы распознавания на клеточной поверхности, содержащие иммуноглобулиновый домен
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DE60239467D1 (de) Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
BR9004967A (pt) Processo para a nitrocarburacao de elementos de construcao de aco
BR0210905A (pt) Anticorpos especìficos para cd44v6
RU2006127049A (ru) Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: IMMUNOGEN, INC. (US)

Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110101858/RJ DE 30/09/2011.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), A61K 39/395 (2006.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time